I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives. 1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

Our new @NEJM piece discusses how CMS’s plan to expand prior authorization in traditional Medicare - using opaque algorithms & private firms with financial incentives to deny care - risks compromising patient care and overburdening clinicians Link: https://t.co/5ca616oQjs

Monoclonal gammopathy of undetermined significance (MGUS) is important not only because it is the precursor to plasma-cell cancers, but also because it is causally related to numerous serious nonmalignant disorders. Learn more in a new review: https://t.co/OiMcemqVJg

Finally in print! 👏Abiola Light chain MM ⬆️ renal failure consequent to a ⬆️ prevalence of t(11;14) & t(6:14). OS for LCMM 🟰 heavy chain MM. ⬇️ PFS noted in the doublet era but no longer the case with triplet/quad induction @myelomaMD @VincentRK

In the Myeloma review from 2004, lenalidomide was still CC-5013, pomalidomide had a cameo as CC-4047. All the other investigational drugs we wrote about did not pan out. None of the combination regimens we list on Table 1 are used anymore. Some principles remain. But the

Two Reviews @NEJM Twenty years apart Two great colleagues Bob Kyle and Shaji Kumar

Glad to have the opportunity to write this Review with @myelomaMD #MGUS @NEJM

𝗠𝗼𝗻𝗼𝗰𝗹𝗼𝗻𝗮𝗹 𝗚𝗮𝗺𝗺𝗼𝗽𝗮𝘁𝗵𝘆 𝗼𝗳 𝗥𝗲𝗻𝗮𝗹 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝗰𝗲 The kidney is particularly vulnerable in clonal plasma-cell disorders; the classic presentation is acute renal failure due to light-chain cast nephropathy in multiple myeloma. But even without

The next time your paper is rejected by a medical journal for reasons that baffle you…

All of this👇Plus it’s under-recognized just how erosive such delays are to the trust at the foundation of the therapeutic alliance 😔 It’s too common to overpromise & under-deliver timely treatment while hacking through the red tape of reflexive denials of the standard of care!

If you read one post today, make it this one. We must do better.

I hear about this. This is not uncommon and it bothers me: Patient has cancer which is getting worse and causing pain Waits days for doctors appointment See the doctor. Scans ordered. But now waits days for an appointment slot to get the scans Scan is done and shows the

I’ll be speaking at this meeting next week. Also speaking are @szusmani @FrancescoMaura4 @UrviShahMD @sridevirajeeve @LesokhinMD and more from @MSKCancerCenter And many of my colleagues from @MayoClinic including @MorieGertz @ADispenzieri @myelomaMD @JoselleCookMD

Monoclonal gammopathy of undetermined significance (MGUS) is a common premalignant plasma-cell proliferative disorder that is present in approximately 5% of the general population over the age of 50 years. This disorder is important not only because it is the precursor to

The men, the myth, the MGUS. @VincentRK @myelomaMD give us the sentinel publication on this topic. A must read. #mmsm.

I am pleased that Heather Cooper Ortner will assume the role of President and CEO of the International Myeloma Foundation. @IMFmyeloma I look forward to working with you and the entire IMF team. Congrats! @SagarLonialMD @NikhilMunshiMD @jmikhaelmd https://t.co/9KsDRfG1wR

Top Heme-Onc Oncologists for Q3 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/VJu7MflQA0 #LARVOL #Hematology #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials | @VincentRK

Very exciting. Welcome Heather!

*Press Release* The International Myeloma Foundation announced Heather Cooper Ortner — President & CEO of Alzheimer’s Los Angeles, & former CEO of the Dr. Susan Love Research Foundation — has been named as the IMF’s new President & Chief Executive Officer. https://t.co/mn0tsmrAK9

Here is a hematology review article that I look forward to reading and I suggest you read it too if you want to know more about MGUS from the best…

Congratulations @VincentRK @myelomaMD! Such a lucid and practical review of a field that is getting ever so complex! 👏👏👏